Jobs
-
Hovione has announced the launch of a new company called Hovione Technology, which “focuses on offering an inhaler that matches your product, your needs, your patients.” The company’s devices include the Twin Caps and PowdAir… Read more . . .
-
Raptor Pharmaceutical has launched Quinsair levofloxacin inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Germany and Denmark, the company said. According to Raptor, it plans to launch Quinsair in… Read more . . .
-
An analysis of data from Boehringer Ingelheim’s WISDOM study showed that withdrawal of ICS for COPD patients using the Spiriva Handihaler tiotropium bromide DPI plus salmeterol is associated with a higher exacerbation rate in patients… Read more . . .
-
In a leading article published in the Archives of Disease in Childhood, Andrew Bush and Louise Fleming of Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College London assert that “the diagnosis… Read more . . .
-
InCarda Therapeutics, which is developing an inhaled treatment for paroxysmal atrial fibrillation, has appointed former Gilead Senior VP for Cardiovascular Therapeutics Luiz Belardinelli as Chief Medical Officer, the company said. Belardinelli will continue as a… Read more . . .
-
Cohero Health and H&T Presspart have announced the availability of a new connected metered dose inhaler (eMDI). The eMDI collects actuation data from an integral sensor and transmits the data via Bluetooth to Cohero Health’s… Read more . . .
-
Chiesi has reported a greater than 9% increase in revenue from 2014 to 2015, with an almost 20% increase in sales of Foster (Fostair) beclamethasone/formoterol inhalers and an unspecified increase in sales of Clenil beclamethasone… Read more . . .
-
On March 10, 2016, the Philadelphia District Office of the FDA issued a warning letter to online retailer Dr Natural Healing about sales of epinephrine capsules packaged with a dry powder inhaler as a treatment… Read more . . .
-
Mundipharma has submitted a marketing application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the flutiform fluticasone/formoterol K-Haler breath-activated MDI for the treatment of asthma, the company said. The submission will be… Read more . . .
-
According to Boehringer Ingelheim Pharmaceuticals, the FDA has approved a supplemental NDA for the Stiolto Respimat tiotropium/olodaterol SMI for a labeling change to add quality of life data obtained from the OTEMTO 1&2 studies. Stiolto… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden